Zobrazeno 1 - 10 of 81 pro vyhledávání: '"Derebail, S"'
1
Akademický článek
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
Autor: Deng S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China., Derebail S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Weiler VJ; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Fong Ng J; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Maroto-Martin E; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Chatterjee M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Giorgetti G; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Chakraborty C; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Kalhotra P; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Du T; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Yao Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China., Prabhala R; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Shammas M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Gulla A; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Aktas Samur A; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Samur MK; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China., Anderson KC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Fulciniti M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Munshi NC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.
Publikováno v: Blood advances [Blood Adv] 2024 Aug 13; Vol. 8 (15), pp. 4025-4034.
Zobrazit plný text záznamu
3
Akademický článek
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Autor: Prabhala R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; VA Boston Healthcare System, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Pierceall WE; Bristol Myers Squibb, Summit, NJ, United States., Samur M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, United States., Potluri LB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Hong K; Bristol Myers Squibb, Summit, NJ, United States., Peluso T; Bristol Myers Squibb, Summit, NJ, United States., Talluri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Wang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Katiki A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Vangala SD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Buonopane M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Bade V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Seah H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Krogman A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Derebail S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Lazo SB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Anderson K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Corre J; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Avet-Loiseau H; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Thakurta A; Bristol Myers Squibb, Summit, NJ, United States.; Oxford Centre for Translational Myeloma Research, Oxford, United Kingdom., Munshi N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; VA Boston Healthcare System, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.
Publikováno v: Frontiers in oncology [Front Oncol] 2023 Dec 04; Vol. 13, pp. 1271807. Date of Electronic Publication: 2023 Dec 04 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Akademický článek
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Autor: Yao Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China., Ng JF; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Park WD; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX., Samur M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Morelli E; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Encinas Mayoral J; University Hospital October 12, Madrid, Spain., Chyra Z; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Xu Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Derebail S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Epstein C; Broad Institute, Cambridge, MA., Nabet B; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA., Chesi M; Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ., Gray NS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford Medical School, Stanford, CA., Young RA; Whitehead Institute for Biomedical Research, Cambridge, MA., Kwiatkowski N; Kymera Therapeutics, Watertown, MA., Mitsiades C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Anderson KC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Lin CY; Kronos Bio, Cambridge, MA., Munshi NC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Fulciniti M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Publikováno v: Blood [Blood] 2023 Jun 08; Vol. 141 (23), pp. 2841-2852.
Zobrazit plný text záznamu
5
Akademický článek
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
Autor: Aktas Samur A; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Biostatistics, Harvard T.H. Chan School of Public Health Boston, Boston, MA, 02115, USA., Fulciniti M; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA., Avet-Loiseau H; University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France., Lopez MA; Memorial Sloan Kettering Cancer Center, New York, 10065, USA., Derebail S; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA., Corre J; University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France., Minvielle S; Inserm UMR892, CNRS 6299, Université de Nantes; Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France., Magrangeas F; Inserm UMR892, CNRS 6299, Université de Nantes; Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France., Moreau P; Inserm UMR892, CNRS 6299, Université de Nantes; Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France., Anderson KC; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA., Parmigiani G; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, 02215, USA. gp@jimmy.harvard.edu.; Department of Biostatistics, Harvard T.H. Chan School of Public Health Boston, Boston, MA, 02115, USA. gp@jimmy.harvard.edu., Samur MK; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, 02215, USA. mehmet_samur@dfci.harvard.edu.; Department of Biostatistics, Harvard T.H. Chan School of Public Health Boston, Boston, MA, 02115, USA. mehmet_samur@dfci.harvard.edu., Munshi NC; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA. nikhil_munshi@dfci.harvard.edu.; VA Boston Healthcare System, Boston, MA, 02115, USA. nikhil_munshi@dfci.harvard.edu.
Publikováno v: Blood cancer journal [Blood Cancer J] 2022 Dec 20; Vol. 12 (12), pp. 171. Date of Electronic Publication: 2022 Dec 20.
Zobrazit plný text záznamu
7
Akademický článek
Successful Derivation of an Induced Pluripotent Stem Cell Line from a Genetically Nonpermissive Enhanced Green Fluorescent Protein-Transgenic FVB/N Mouse Strain.
Autor: Abbey D; Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India., Singh G; Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India.; Present address: Centre for Stem Cell Research, Christian Medical College Campus, Bagayam, Vellore, India., Verma I; Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India., Derebail S; Thermo Fisher Scientific, Frederick, Maryland., Kolkundkar U; Thermo Fisher Scientific, Frederick, Maryland., Chandrashekar DS; Institute of Bioinformatics and Applied Biotechnology, Bangalore, India., Acharya KK; Institute of Bioinformatics and Applied Biotechnology, Bangalore, India., Vemuri MC; Thermo Fisher Scientific, Frederick, Maryland., Seshagiri PB; Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India.
Publikováno v: Cellular reprogramming [Cell Reprogram] 2019 Oct; Vol. 21 (5), pp. 270-284.
Zobrazit plný text záznamu
8
Akademický článek
Bioorthogonal non-canonical amino acid tagging to track transplanted human induced pluripotent stem cell-specific proteome.
Autor: Sridharan, Divya1 (AUTHOR), Dougherty, Julie A.1 (AUTHOR), Ahmed, Uzair1 (AUTHOR), Sanghvi, Shridhar K.2,3 (AUTHOR), Alvi, Syed Baseeruddin1 (AUTHOR), Park, Ki Ho4 (AUTHOR), Islam, Helena1 (AUTHOR), Knoblaugh, Sue E.5 (AUTHOR), Singh, Harpreet2 (AUTHOR), Kirby, Elizabeth D.6,7 (AUTHOR), Khan, Mahmood1 (AUTHOR) Mahmood.Khan@osumc.edu
Publikováno v: Stem Cell Research & Therapy. 6/26/2024, Vol. 15 Issue 1, p1-17. 17p.
Zobrazit plný text záznamu
9
Akademický článek
放射線による組織反応の惹起と時空間ダイナミクス.
Autor: 鈴木 啓司1 kzsuzuki@nagasaki-u.ac.jp
Publikováno v: Radiation Biology Research Communications / Houshasen Seibutsu Kenkyuu. 2024 Supplement, Vol. 59 Issue 1, p2-57. 56p.
Zobrazit plný text záznamu
10
Akademický článek
Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation.
Autor: Gong, Lixin1,2 (AUTHOR) gonglixin@ihcams.ac.cn, Qiu, Lugui1,2,3 (AUTHOR) qiulg@ihcams.ac.cn, Hao, Mu1,2 (AUTHOR) qiulg@ihcams.ac.cn
Publikováno v: Cancers. Feb2024, Vol. 16 Issue 3, p498. 20p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje